Search clinical trials for: RPV

Total 61 results

National Institute of Allergy and Infectious Diseases...

Not yet recruiting

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Pregnancy | HIV-1-infection | Postpartum

United States, South Africa
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Recruiting

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (HOLA)

HIV-1 Infection

Spain
Instituto de Investigación Sanitaria de la Fundación...

Not yet recruiting

Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (IMAdART)

HIV Infections
Gilead Sciences

Recruiting

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

HIV-1-infection

United States, France, Canada
Rhode Island Hospital

Recruiting

Combined Injectable Treatment for HIV and OUD (CHOICE)

Opioid Use Disorder | Human Immunodeficiency Virus

United States
Public Health Foundation Enterprises, Inc.
ViiV Healthcare; San Francisco Department of Public Health; Lyon-Martin Community...

Recruiting

The Cheeky Study: A Novel Delivery System for CAB-RPV LA

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline; PPD

Recruiting

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOLITION)

HIV Infections

United States, Italy, Spain, Argentina, Germany, France, Canada, Chile, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

HIV-1-infection

United States, Brazil, South Africa, Uganda, Botswana, Thailand
Seoul National University Hospital

Not yet recruiting

RPVI for Fluid Responsiveness in Children

Anesthesia | Fluid Responsiveness
C. R. Bard

Recruiting

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System (CONNECT-AV)

Arteriovenous Fistula | End-stage Renal Disease | Kidney Disease, End-Stage

United States
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Recruiting

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Recruiting

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA)

HIV Infections

Thailand, United States, Puerto Rico, Botswana, South Africa, Uganda
Janssen Research & Development, LLC

Completed

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

HIV

Italy, Thailand, Spain, Uganda, Portugal, South Africa
University College, London
London School of Hygiene and Tropical Medicine; MRC/UVRI and LSHTM Uganda Research... and other collaborators

Active, not recruiting

Long-Acting Treatment in Adolescents (LATA) (LATA)

HIV Infections | Hiv | HIV-1-infection | Paediatric Human Immunodeficiency Virus Infection

Uganda, Zimbabwe, Kenya, South Africa
Janssen Research & Development, LLC

Active, not recruiting

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Healthy

United States, Netherlands
ViiV Healthcare
Janssen Pharmaceuticals

Completed

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

HIV Infections

Germany, Netherlands, France, Belgium, Spain
Allegheny Singer Research Institute (also known...

Active, not recruiting

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA (CAPRI)

HIV Infections | HIV-1-infection | HIV I Infection

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada, Australia, Korea, Republic of, Italy, South Africa, Russian Federation, Argentina, Mexico, Sweden
Fundacion SEIMC-GESIDA

Active, not recruiting

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (MAFALDA-R)

HIV Infections | Fatty Liver Disease

Spain
ViiV Healthcare
Janssen Research and Development

Active, not recruiting

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults (ATLAS-2M)

HIV Infections

United States, Germany, Spain, France, Canada, Korea, Republic of, Italy, South Africa, Australia, Russian Federation, Mexico, Sweden, Argentina
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

HIV Infections

Germany, Taiwan, France, United States, Canada, Belgium, Australia, Netherlands, Spain, United Kingdom, Italy, Argentina, Russian Federation
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

HIV Infections

Germany, Spain, United States, Canada, Taiwan, France, Italy, Argentina, United Kingdom, Russian Federation, Australia
ViiV Healthcare

Completed

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

HIV Infections

Spain
Boston Medical Center
ViiV Healthcare

Completed

Improving Treatment and Retention Adherence in Nontraditional Settings (I-TRAINS)

HIV Infections

United States
ViiV Healthcare
Janssen Research and Development

Completed

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Human Immunodeficiency Virus Type 1 (HIV-1)

Germany, Spain, United States, Italy, Canada, Argentina, Sweden
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Withdrawn

Pharmacokinetic Interactions of ENG Subdermal Implants With Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)

HIV-1-infection
Masimo Corporation

Terminated

Validation of RPVi as a Parameter to Predict Fluid Responsiveness

Surgery | Anesthesia

United States
ViiV Healthcare

Completed

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

HIV Infections

United States
ViiV Healthcare
Janssen, LP

Completed

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

HIV Infections

United States, Canada
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
Rovi Pharmaceuticals Laboratories

Completed

Comparative Bioavailability of Risperidone

Schizophrenia

United States
National Institute of Allergy and Infectious Diseases...
National Institute of Mental Health (NIMH)

Withdrawn

Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age

HIV Infections
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
Janssen Sciences Ireland UC
ViiV Healthcare

Approved for marketing

Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

HIV
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (SALIF)

Human Immunodeficiency Virus-type 1 Infection

South Africa, Kenya, Thailand, Uganda, Cameroon, Senegal
ASST Fatebenefratelli Sacco
Elisa Colella, M.D.; Valentina Di Cristo, M.D.; Massimo Galli, M.D.

Completed

DRV/r + RPV QD: Efficacy and Toxicity Reduction

Human Immunodeficiency Virus

Italy
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
Nantes University Hospital

Completed

Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV (AES ODEFSEY)

Hiv

France
A.O. Ospedale Papa Giovanni XXIII
San Raffaele University Hospital, Italy

Unknown

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection (PROBE2)

HIV Infection

Italy
Chiang Mai University

Unknown

Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine

HIV-1-infection | Neurocognitive Dysfunction

Thailand
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
Mahidol University

Completed

Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression (STEREOS)

Dyslipidemias | HIV-1-infection | Sustained Virologic Response | Anti-Retroviral Agents | Efavirenz | Rilpivirine
Hospices Civils de Lyon

Completed

Comparison of PVI and RPVI (RPVI)

Venous; Return (Anomaly)

France
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
Azienda Ospedaliera San Gerardo di Monza
Gilead Sciences

Completed

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (SWEAR)

Quality of Life | HIV-1 Infection | Impaired Cognition | Poor Quality Sleep | Depression/Anxiety

Italy

3

Subscribe